Omniab, Inc. · NASDAQ:OABI
Omniab — Q3 2025 Earnings Presentation
24 slides from Omniab's earnings presentation, Nov 4, 2025
Slide 1: Q3 2025 Financial Results & Business Update
1 Q3 2025 Financial Results & Business Update Nasdaq: OABI November 4, 2025
Slide 2: Disclaimer
2 Disclaimer We caution you that this presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, including our financial guidance fo
Slide 3: Introduction
Omni Introduction - Matt Foehr
Slide 4: Q3 2025 and Recent Highlights
4 Q3 2025 and Recent Highlights Partner and program additions remain strong, pipeline advancement continues, facilitated by our highly differentiated technologies Building foundation for the xPloration® business OmniUltra – a significant new technology launch is scheduled for December, potentially o
Slide 5: Active Partners
5 Active Partners Q3 2025: 104 ACTIVE PARTNERS Number of Active Partners Partner Type 104 Academic 13% Discovery 66% • We continue to grow and diversify our Commercial partnership base, with 104 Active Partners 21% as of 9/30/2025 n=104 • New licenses added in Q3 include those Partner Location with
Slide 6: Active Programs
6 Active Programs Q3 2025: 399 ACTIVE PROGRAMS YTD 2025 Change in Number of Active Programs Active Programs 399 400 69 399 • 399 Active Programs as of 363 9/30/2025 (33) • Net addition of 36 programs 200 year-to-date, showing continued strength 0 See our SEC filings for Active Program definition
Slide 7: Post-Discovery Stage Programs
7 Post-Discovery Stage Programs 15% GROWTH OVER THE LAST 12 MONTHS As of 9/30/2024 As of 9/30/2025 Registration: 1 Approved: 3 Registration: 2 Approved: 3 Phase 3: 3 Preclinical: 20 Phase 3: 5 • Total milestones of ~$1.3 billion Phase 2: 2 Phase 2: 2 for Post-Discovery stage Preclinical: 29 programs
Slide 8: Active Clinical Programs and Approved Products
8 Active Clinical Programs and Approved Products Number of Active Clinical Programs and Approved Products(1)(2) 32 30 • 32 active clinical programs and approved products as of 9/30/2025 • First OmnidAb-derived partner program has now entered human clinical trials, less than 2 years after the launch
Slide 9: Select Partner Updates
9 Select Partner Updates Batoclimab/IMVT-1402 SAL003 Zimberelimab RNDO-564 FcRn Anit-PCSK9 Anti-PD-1 CD28 x Nectin-4 Immunovant presented an abstract at China’s National Medical Products Arcus Biosciences presented the first Rondo Therapeutics’ abstract titled the 2025 Annual Meeting of the Administ
Slide 10: Clinical and Commercial-Stage Partner Pipeline
Clinical and Commercial-Stage Partner Pipeline 10 (1)(2) AS OF 9/30/2025 ONLY PROGRAMS WITH DOWNSTREAM ECONOMICS ARE SHOWN Phase 1 Phase 2 Phase 3 Registration Approved Johnson & Johnson Aptevo Therapeutics CTTQ Pharma JNJ-70218902 Mipletamig TQB2223 Gloria Biosciences, Arcus Biosciences, TMEFF2 x C
Slide 11: xPloration Platform
11 xPloration Platform PARTNER ACCESS PROGRAM XPLORATION PLATFORM OFFERING INCLUDES: COMPETITIVELY-PRICED INSTRUMENT PROPRIETARY, SINGLE-USE CONSUMABLES ANNUAL SOFTWARE SUBSCRIPTION • Deployed instruments performing for partners and driving efficiencies MAINTENANCE CONTRACTS • Strong demand for inst
Slide 12: Innovation Continues to Differentiate OmniAb
12 Innovation Continues to Differentiate OmniAb NOVEL CHICKEN-BASED PLATFORMS PRODUCING HUMAN SEQUENCES Ultralong CDRH3s Single domain framework Fixed light chain for bispecific applications Evolutionary divergent host system for robust immune responses
Slide 13: Upcoming New Technology Launch - OmniUltra
13 Upcoming New Technology Launch - OmniUltra PLANNED LAUNCH AT ANTIBODY ENGINEERING & THERAPEUTICS CONFERENCE IN DECEMBER OmniUltra is the first and only transgenic chicken producing antibodies with ultralong CDRH3s; a feature of antibodies found in cows. Ultralong CDRH3s are designed to reach bind
Slide 14: New Opportunities - OmniUltra
14 New Opportunities - OmniUltra ANTIBODY AND PEPTIDE THERAPEUTICS DISCOVERY APPLICATIONS New Antibody Discovery Platform Along with its unique architecture, OmniUltra is also engineered for in vivo optimization, enabling generation of molecules that are pre- selected for function, affinity, and str
Slide 15: Upcoming OmniUltra Presentations & Events
15 Upcoming OmniUltra Presentations & Events December 15th-18th San Diego Empowering the efficient discovery of ultralong OmniUltra: A new in vivo platform for discovery CDRH3 antibodies with high-throughput of novel mini-proteins and structured peptides xPloration® workflows Development of OmniUltr
Slide 16: Potential Program IP Extension
16 Components of Technology Licenses DEALS CAN CREATE MULTIPLE SOURCES OF REVENUE AND VALUE FOR STAKEHOLDERS Royalties Can create durable and Potential Program IP Extension stackable revenue Milestones streams as programs Collaboration/ reach the market Service Event-driven • Significantly increases
Slide 17: Financial Updates
17 Financial Updates Kurt Gustafson
Slide 18: Q3 2025 Revenue
18 Q3 2025 Revenue $ in millions • xPloration revenue includes consumables sales $4.2 $4 License & • License and Milestone revenue was lower due to Milestone lower milestone revenue $2.2 xPloration • Service revenue decreased primarily due to the $2 License & completion of a small-molecule ion chann
Slide 19: Q3 2025 Costs and Operating Expense
19 Q3 2025 Costs and Operating Expense $ in millions $25 $23.9 • Research and Development expense decreased Other primarily due to lower stock-based compensation $20.4 $20 expense and headcount, as well as lower external Other expenses associated with small-molecule ion G&A channel programs $15 G&A
Slide 20: Q3 2025 vs. Q3 2024 Financial Results
20 Q3 2025 vs. Q3 2024 Financial Results (in millions, except per share data) Q3 2024 Q3 2025 Variance License and milestone revenue $ 1.4 $ 0.6 ($ 0.8) Service revenue 2.5 1.2 (1.3) xPloration revenue 0.0 0.1 0.1 Royalty revenue 0.3 0.4 0.1 Total revenue 4.2 2.2 (1.9) Cost of xPloration revenue - 0
Slide 21: Balance Sheet
21 Balance Sheet (in millions) December 31, September 30, 2024 2025 ASSETS Current assets: Cash & investments $ 59.4 $ 59.5 Accounts receivable, net 5.3 3.1 Other current assets 3.4 3.8 Goodwill & intangible assets 222.0 212.4 PPE & leases 33.3 29.4 Other assets 2.1 1.5 Total assets $ 325.6 $ 309.7
Slide 22: 2025 Guidance
22 2025 Guidance • We now expect revenue to be in the range of $18 to $22 million • We now expect operating expense to be in the range of $82 to $86 million • 2025 cash use is expected to be lower than cash use in 2024, excluding financings • We expect to end the year with cash between $52 and $56 m
Slide 23: Q&A
Omni Q&A
Slide 24: Omni >
Omni >